P&G's fiscal Q3 organic growth came in at 1%, the lowest print since 2020. Volume has stalled, price/mix is decelerating, and the consensus is treating it as transitory. The data says structural.
P&G reported fiscal 2025 (year ended June 30, 2025) revenue of $84.3 billion, up just 0.3% from $84 billion the prior year. The gross margin held at 51%, and operating income expanded to $20.5 billion. On the surface, the print looks fine. The composition is the problem.
P&G's revenue growth over the last 36 months has been almost entirely price-led. Organic volume has been negative or flat for six consecutive quarters. The company's pricing power, which compounded above 8% during fiscal 2022 and 2023, decelerated to 4% in fiscal 2024 and is now running at 2-3% in fiscal 2025. Price-led growth without volume recovery is a finite resource. The data says the resource is now exhausted.
The market reaction to the most recent earnings was relatively mild. The stock moved 3% lower on the print and recovered within a week. The Signals Desk reads the lack of reaction as the market mistaking a structural inflection for cyclical noise. The pricing wall hit in this quarter is not a one-off; it is the consequence of three consecutive years of consumer absorbing price increases that exceeded wage growth in the lower two income quartiles.
Between fiscal 2022 and fiscal 2024, P&G captured approximately 18% of cumulative price/mix growth across the consumer brand portfolio. The pricing actions were genuine and well-executed: SKU optimisation, premiumisation, format upgrades. The volume cost was real but absorbed by the inflation environment. Consumers paid more because everyone was charging more. In a real terms framework, P&G's pricing held the company's share of wallet despite higher absolute spend.
The regime changed in calendar 2024. CPI moderated from 9% peaks toward 3%. Wage growth in the lower income quartiles slowed from 6% annual rates to 3.5%. The discretionary cushion that had absorbed staples pricing through 2022 and 2023 evaporated. The first signal was private label share recovery in 2024 (Costco's Kirkland brand expanded category share by 2-3 percentage points across detergents, paper, and pet care). The second was P&G's volume turning negative in fiscal Q4 2024.
The management response has been to pull back on pricing while maintaining premium positioning. The fiscal 2025 guidance assumed volume returning to positive growth as price moderation removed the consumer barrier. The fiscal Q3 2026 print disconfirmed that assumption. Volume was flat. Pricing decelerated to 2%. Organic growth was 1%. The bridge management built between the inflation pricing cycle and the next volume cycle has not actually arrived.
TickerXray Report
Get the complete Procter & Gamble report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
P&G is currently guiding to 3-4% organic growth in fiscal 2026. The Signals Desk's forward model implies 1-2% based on the fiscal 2026 to-date data. Consensus is anchored to 3%. The earnings sensitivity is meaningful: every percentage point of organic growth shortfall translates to roughly $0.20 of EPS, against fiscal 2026 consensus EPS of approximately $7. A 1.5 percentage point organic miss compresses EPS by 4-5%.
The operating margin trajectory is the secondary concern. P&G expanded operating margin by 270 basis points from fiscal 2021 to fiscal 2025. The expansion was funded by pricing leverage (gross margin held while SG&A as a percent of revenue declined as fixed cost was spread across higher revenue). At slowing revenue growth, the SG&A leverage reverses. Add to this the input cost picture: pulp, surfactants, and palm oil prices have stabilised but remain 30-40% above 2019 levels. Without continued pricing, gross margin compresses.
The regional decomposition is informative. Greater China, which historically represented approximately 10% of P&G revenue, has been a persistent drag with organic growth running at negative 5-10%. The China weakness is structural (the consumer is rebalancing toward domestic brands and value-oriented international competitors). The fiscal 2026 P&G plan assumes Greater China stabilising in the back half. The fiscal Q3 2026 print showed Greater China still declining, which means the back-half assumption is now hostage to a fourth-quarter inflection that the data does not support.
Unilever, post-Hein restructuring, has accelerated organic growth to 4-5%. Colgate-Palmolive is growing organically at 4-5%, with toothpaste pricing power genuinely intact. Reckitt Benckiser, despite the well-documented portfolio drama, has volume growing positively. P&G is the laggard in the staples group on volume specifically.
The peer multiple gap is narrow. Colgate trades at 27x earnings, Unilever at 22x, Reckitt at 17x, P&G at 22x. P&G's premium has historically rested on superior brand quality and the operating margin structure that comes with scale. The brand quality argument remains intact. The operating margin advantage is being eroded by the volume stall. If fiscal 2026 organic growth comes in below 2%, the P&G premium versus Colgate is, frankly, hard to defend. The valuation case is one earnings cycle from a multiple compression.
P&G is a high-quality compounder going through a meaningful pricing-to-volume transition. The transition is harder than the management commentary implies. The historical analog is the period from 2014 to 2017 (post-A.G. Lafley return), during which P&G operated through a similar volume reset and the stock returned approximately zero against an 8% annualised dividend yield contribution. Fair value at $145, a small discount to current levels, with a catalyst-required setup. We need to see two consecutive quarters of positive volume growth and Greater China stabilisation before the multiple supports further upside. Until then, the Signals Desk reads P&G as a fairly valued income stock, not a compounding growth name. The capital allocation discipline is intact (dividend coverage above 1.5x), but the multiple expansion case is dependent on a volume inflection that the most recent quarter did not deliver.
Full forensic analysis of Procter & Gamble
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
The consensus has been buying P&G as a safe defensive name through the consumer cycle. Underneath the headline, volume growth has been flat to negative for six quarters, emerging market FX exposure is widening, and the dividend coverage is tightening. The premium is mispriced.
Both names trade as defensive consumer staples with disciplined capital return frameworks. The capital allocation choices, the brand reinvestment intensity, and the international exposure produce different risk-reward profiles that the headline yields obscure.
The 70th consecutive annual raise reads as a cliche. The capital allocation math behind it does not. PG has returned more than $110 billion to shareholders over the last decade while growing per-share free cash flow faster than the headline revenue growth rate suggests.